SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
ContractWarrant Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT, OR PRE-FUNDED WARRANTS IN LIEU THEREOF (THE “SECURITIES”), HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October [●], 2024, is entered into by and among Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
VIADirector Offer Letter • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Director Offer Letter constitutes an agreement (“Agreement”) between you and Inhibikase Therapeutics, Inc. (“Company”) and contains all of the terms and conditions relating to your service to the Company as a Class [•] member of our Board of Directors (“Board”).
SETTLEMENT AGREEMENTSettlement Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Settlement Agreement is made on this 30th day of September 2024 and entered into by and between Inhibikase Therapeutics, Inc. (“Inhibikase”), and Pivot Holding LLC (“Pivot”), as successor in interest to Sphaera Pharma Pte. Ltd. (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd. (“Sphaera India,” and together with Sphaera Singapore, “Sphaera”) (collectively, Inhibikase and Pivot are the “Parties,” and each a “Party” to this Settlement Agreement).
SUPPORT AGREEMENTSupport Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This SUPPORT AGREEMENT (this “Agreement”) is entered into as of October [●], 2024, by and between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and the investor whose name appears on the signature page hereto (the “Stockholder”).
